<DOC>
	<DOCNO>NCT00203099</DOCNO>
	<brief_summary>This study evaluate effect therapy combine GA NAC disease activity reflect MRI parameter assess tolerability safety .</brief_summary>
	<brief_title>Safety Efficacy Study Copaxone Administered Combination With N-Acetylcysteine</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Clinically Definite Multiple Sclerosis ( CDMS ) define Poser et al ( Ann Neurol 1983 ) . 2 . Subjects must least one T1 Gdenhancing lesion one pretreatment MRI scan . 3 . Subjects must relapsingremitting disease course . 4 . Subjects must least one document relapse within last year prior screen visit ( week 10 ) . 5 . Subjects must relapsefree take corticosteroid ( IV , IM and/or PO ) within 30 day prior screen visit . 6 . Subjects may male female . Women child bear potential must practice medically acceptable method birth control . Acceptable method include oral contraceptive doublebarrier method ( condom IUD spermicide ) . 7 . Subjects must age 18 50 year inclusive . 8 . Subjects must ambulatory , Kurtzke EDSS score 0 5.0 inclusive . 9 . Subjects must willing able give write informed consent prior enter study . 1 . Previous use inject glatiramer acetate . 2 . Previous use cladribine within 2 year prior screen visit ( week 10 ) . 3 . Previous use immunosuppressive agent last 6 month . 4 . Use experimental investigational drug , include I.V . immunoglobulin , within 6 month prior study entry . 5 . Use interferon agent within 60 day prior screen visit . 6 . Chronic corticosteroid ( IV , IM and/or PO ) treatment ( 30 consecutive day ) 6 month prior study entry . 7 . Chronic use antioxidant substance ( ) , include NAC , ( 30 consecutive day ) within 60 day prior screen visit . 8 . Previous total body irradiation total lymphoid irradiation ( TLI ) . 9 . Pregnancy breastfeed . 10 . Significant medical psychiatric condition affect subject 's ability give inform consent , complete study , condition investigator feel may interfere participation study ( e.g . alcohol drug abuse ) . 11 . A known history uncontrolled asthma . 12 . A known history sensitivity mannitol acetylcysteine . 13 . Inability successfully undergo MRI scanning .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>